BIOCAD and SPH Agree to Build a Drug Substance Manufacturing Facility in China
SAINT PETERSBURG, Russia--(BUSINESS WIRE)--This year at the Eastern Economic Forum in Vladivostok, BioCad and Shanghai Pharmaceutical Holding entered into a Memorandum of Understanding to create two joint ventures for production, clinical development, registration, and marketing of several high-cost medicines based on monoclonal antibodies in the People's Republic of China.
Russian Private Equity Fund announced the closing of a deal with the pharmaceutical company R-Pharm Alexey Repyk. The share of the company bought by the joint Russian-Japanese equity fund is estimated at 10%, the deal value is not disclosed.
Active Component has attracted a minority financial investor to the company
Elbrus Capital II, a private equity fund, has announced investment in Active Component.
The Presidium of the Presidential Council for Strategic Development has approved the national «Healthcare» project with a budget of 1.3 trillion rubles
The President’s Council of the Russian Federation on strategic development and national projects has approved the national project "Healthcare". For its execution, more than 1.3 trillion rubles will be invested within six years,-said Veronika Skvortsova, Minister of Health, at the meeting of the Presidium of the Council...
Gilead Sciences has concluded an agreement on the production of Sovaldi (sophosbuvir) for the treatment of chronic hepatitis C and Truvada (tenofovir + emmitcytabin) for the treatment of the HIV on Pharmstandard facilities. The issue of inclusion of drugs in EDL list will be considered by the specialized commission of the Ministry of Health on September 4...
The Cabinet of Ministers rejected the idea to allow the sale of pharmaceuticals in grocery stores
In Russia nonprescription drugs will not be sold in trade networks, Kommersant reports. The bill draft, ratifying cease of the monopoly of pharmacies for these drugs, was criticized by representatives of the pharmaceutical industry and the Ministry of Health.
High expectations of pharmaceutical manufacturers on the dynamics of sales in the Russian retail market led to the excess of some distributors’ trade stocks in early 2018. This situation is being solved in different ways: someone tries to convince manufacturers to adjust the sales plan, someone interchanges bonuses and volume.
Senators have approved amendments to the law "On medicine circulation", allowing companies to register generics under one international non-proprietary name, but under different brand names. It expands the possibilities of contract manufacturing for domestic pharmaceutical manufacturers...
Biocad Biotechnology Company has signed an agreement with The Almazov National Medical Research Centre on conducting joint research in the field of treatment of cancer with the help of chimeric antigenic receptors (CAR-T). The head of Biocad Dmitry Morozov promised that the cost of creating an individual cellular immune drug for one patient will amount to 16 million rubles – half as cheap as imported analogues...
© All rights reserved, 2015-2018